On June 16, Insilico Medicine fell 5.1% in regular trading, trading at 32.9 HKD/share, with turnover of approximately 18.11 million HKD. The decline erased most of the prior session's gains driven by index inclusion.

On the news front, approximately 453 million shares held by cornerstone investors and employees are set to be unlocked on June 29 upon lock-up expiry, representing 81.25% of total shares outstanding. Although the company was formally included in the CSI Hong Kong Stock Connect Innovative Drug Index, CSI Hong Kong Innovative Drug Index, and CSI Hong Kong Stock Connect Healthcare Index effective June 15 — which briefly lifted sentiment — market concerns over imminent concentrated selling pressure have quickly reasserted dominance. Fundamentally, the company reported a 34.48% year-over-year revenue decline with a net loss attributable to shareholders of USD 352 million, offering limited valuation support.

Within the Life Sciences Tools and Services sector, WUXI BIO fell 1.94%, XTALPI fell 2.59%, WUXI XDC fell 2.4%, and GENSCRIPT BIO fell 2.46%, reflecting broad sector weakness that further weighed on sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)